WO1997047253A1 - Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur - Google Patents
Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur Download PDFInfo
- Publication number
- WO1997047253A1 WO1997047253A1 PCT/US1997/010024 US9710024W WO9747253A1 WO 1997047253 A1 WO1997047253 A1 WO 1997047253A1 US 9710024 W US9710024 W US 9710024W WO 9747253 A1 WO9747253 A1 WO 9747253A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- blood vessels
- cardiac function
- myocardial perfusion
- angiogenic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 230000004217 heart function Effects 0.000 title claims abstract description 23
- 230000010412 perfusion Effects 0.000 title claims abstract description 23
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 22
- 206010002383 Angina Pectoris Diseases 0.000 title claims description 23
- 230000002708 enhancing effect Effects 0.000 title claims description 13
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 45
- 239000000126 substance Substances 0.000 claims abstract description 43
- 230000012010 growth Effects 0.000 claims abstract description 20
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 19
- 210000002216 heart Anatomy 0.000 claims abstract description 19
- 230000004936 stimulating effect Effects 0.000 claims abstract description 19
- 230000005855 radiation Effects 0.000 claims abstract description 10
- 210000004165 myocardium Anatomy 0.000 claims description 23
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 11
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
- A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00392—Transmyocardial revascularisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/062—Apparatus for the production of blood vessels made from natural tissue or with layers of living cells
Definitions
- the field of this invention concerns methods and devices for the treatment of disorders related to decreased myocardial perfusion and cardiac function, and, in particular, methods and devices for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function.
- Various surgical and pharmaceutical procedures have been used to attempt to enhance myocardial perfusion and/or cardiac function.
- One such procedure currently being evaluated in human clinical trials is transmyocardial laser revascularization (TMLR) in which a laser is directed to the heart and traverses the myocardium.
- TMLR transmyocardial laser revascularization
- TMLR transmyocardial laser revascularization
- TMLR transmyocardial laser revascularization
- TMLR as currently practiced has not shown success in all instances, however. Levels of success rates are also variable. In addition, some
- SUMMARY OF THE INVENTION Methods and devices are disclosed for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function.
- the present invention is based on the novel recognition by the inventor that the administration to a patient of angiogenic substances capable of stimulating the growth of blood vessels in combination with TMLR procedures and/or procedures for forming channels in the myocardium, can improve the reduction of angina pain, the enhancement of myocardial perfusion and/or the increase in cardiac function currently associated with TMLR procedures.
- the inventor has recognized that administering angiogenic substances in conjunction with TMLR procedures and/or procedures for forming channels in the myocardium can expand the pool of patients who would benefit from treatment to reduce angina, to enhance myocardial perfusion and/or to increase cardiac function.
- Myocardial perfusion includes blood flow to the heart tissue including myocardium, sub-endocardium, endocardium, sub-epicardium, and/or epicardium.
- Angiogenic substances include substances capable of stimulating the growth of blood vessels.
- Channels include holes, lumens or passageways, and other perforations in the heart.
- TMLR procedures include procedures for directing a beam of radiation to heart tissue.
- methods for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function include
- the method can involve producing the radiation from a laser, such as a carbon dioxide laser or other radiation producing elements known to those of ordinary skill in the art; and/or forming at least one channel in the myocardium.
- the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
- the method can also be employed in conjunction with implanting and or removing at least one ventricular assist device (VAD).
- VADs hereinafter can include left, right or bi- ventricular assist devices.
- the angiogenic substance capable of stimulating the growth of blood vessels in the patient can include an angiogenic growth factor.
- the angiogenic growth factor can include vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) in native and/or non-native forms.
- VEGF vascular endothelial growth factor
- VPF vascular permeability factor
- the angiogenic growth factor also can include a fibroblast growth factor, such as a basic fibroblast growth factor (bFGF or FGF- 2), in native and/or non-native forms, and/or acidic fibroblast growth factor (aFGF or FGF-1), in native and/or non-native forms.
- bFGF or FGF-2 basic fibroblast growth factor
- aFGF or FGF-1 acidic fibroblast growth factor
- angiogenic substances include, but are not limited to, platelet-derived growth factor (PDGF) such as PDGF-AA, PDGF-BB, and PDGF-AB; hepatocyte growth factor/scatter factor (HGF/SF); placenta growth factor; endothelial cell growth factor (ECGF); platelet-derived endothelial cell growth factor (PD-ECGF); and urokinase plasminogen activator (uPA).
- PDGF platelet-derived growth factor
- HGF/SF hepatocyte growth factor/scatter factor
- ECGF endothelial cell growth factor
- PD-ECGF platelet-derived endothelial cell growth factor
- uPA urokinase plasminogen activator
- the angiogenic substance can be administered to the patient in a variety of ways.
- methods of administering the angiogenic substance include one or more of the following steps; directly injecting the angiogenic substance into the atria, the ventricles, the veins, the arteries, and/or the formed channels; applying a slow-release formulation of the angiogenic substance into the formed channels; administering a slow-release formulation of the angiogenic substance orally, and/or via a skin patch; applying a material, such as a biologically compatible or incompatible, resorbable or non-resorbable material, contacted with the angiogenic substance, over the surface of the heart; and infusing the angiogenic substance into the patient via a pump connected to the atria, the ventricles, the veins, the arteries, and/or the formed channels.
- methods of administering the angiogenic substance include one or more of the following steps: implanting a catheter, such as a slow-release catheter, contacted with the angiogenic substance, into the atria, the ventricles, and/or the formed channels; loading a sleeve, such as an infusion sleeve, contacted with the angiogenic substance, over a catheter and introducing the catheter into the formed channels; applying bead carriers, such as heparin- alginate beads, contacted with the angiogenic substance, over the epicardial and/or endocardial surfaces of the heart; inserting an implant, such as a fibrin-glue implant, contacted with the angiogenic substance, between, for example, the aorta and the myocardium, and/or in other positions of the epicardial and/or endocardial surfaces; injecting retroviral and/or non-retroviral vectors enclosing a gene for the angiogenic substance into the myocardi
- methods for reducing angina pain, and/or enhancing myocardial perfusion and/or cardiac function include forming at least one channel in the myocardium of a patient, and administering to the
- the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
- the method can also be employed in conjunction with implanting and/or removing a VAD.
- the angiogenic substances and/or methods for administering the same discussed above can be used.
- methods for reducing angina pain, and/or enhancing myocardial perfusion and/or cardiac function include forming at least one channel in the myocardium of the patient, and inserting into the channel at least one stent contacted with one or a mixture of angiogenic
- the stent can be biologically compatible or incompatible, and the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
- the method can also include implanting and/or removing a VAD.
- the angiogenic substances and/or methods for administering the same discussed above can be used with these aspects of the invention.
- devices for reducing angina pain, and/or enhancing the myocardial perfusion and/or cardiac function of a patient include a stent contacted with at least one angiogenic substance capable of stimulating the growth of blood vessels in the patient and adapted for insertion into a channel formed in a myocardium of the heart of the patient.
- the stent can be biologically compatible or non-compatible, resorbable or non-resorbable.
- the devices of the invention can be self-expanding; and/or can further include an element for expanding the stent from a first to a second position.
- the angiogenic substances discussed above can be used in these aspects of the invention.
- devices for reducing angina in a patient and/or enhancing the myocardial perfusion and/or cardiac function of a patient include an element for directing a selected beam of radiation for a pre-determined time period to a heart of the patient, and an element for administering to the patient at least one angiogenic substance capable of stimulating growth of blood vessels in the patient.
- the angiogenic substances discussed above can be used in these aspects of the invention.
- devices for reducing angina in a patient and/or enhancing the myocardial perfusion and/or cardiac function of a patient include an element for forming at least one channel in a myocardium in a heart of the patient, and an element for administering to the patient at least one angiogenic substance capable of stimulating growth of blood vessels in the patient.
- the angiogenic substances discussed above can be used in these aspects of the invention.
- the present invention benefits from the recognition that TMLR procedures and/or procedures for forming channels in the myocardium can be performed in conjunction with the administration of angiogenic substances capable of stimulating the growth of blood vessels in a patient.
- the methods and devices of the present invention have several advantages over the prior art.
- the present invention can improve in patients the level of angina pain reduction, and/or enhance myocardial perfusion and/or cardiac function. Accordingly, the present invention can improve the treatment of disorders associated with reduced myocardial perfusion such as angina and/or improve cardiac functions in patients experiencing different levels of heart failure. In addition, the present invention can expand the pool of patients who can be eligible for TMLR procedures and/or procedures involving the formation of channels in the myocardium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Otolaryngology (AREA)
- Electromagnetism (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33085/97A AU3308597A (en) | 1996-06-14 | 1997-06-11 | Methods and devices for reducing angina, enhancing myocardial perfusion and increasing cardiac function |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2048296P | 1996-06-14 | 1996-06-14 | |
US60/020,482 | 1996-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047253A1 true WO1997047253A1 (fr) | 1997-12-18 |
Family
ID=21798856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/010024 WO1997047253A1 (fr) | 1996-06-14 | 1997-06-11 | Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3308597A (fr) |
WO (1) | WO1997047253A1 (fr) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925012A (en) * | 1996-12-27 | 1999-07-20 | Eclipse Surgical Technologies, Inc. | Laser assisted drug delivery |
WO1999039624A1 (fr) * | 1998-02-05 | 1999-08-12 | Biosense Inc. | Administration de medicament intracardiaque |
US5999678A (en) * | 1996-12-27 | 1999-12-07 | Eclipse Surgical Technologies, Inc. | Laser delivery means adapted for drug delivery |
US6067988A (en) * | 1996-12-26 | 2000-05-30 | Eclipse Surgical Technologies, Inc. | Method for creation of drug delivery and/or stimulation pockets in myocardium |
US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
US6254573B1 (en) | 1998-02-05 | 2001-07-03 | Biosense, Inc. | Intracardiac drug delivery device utilizing spring-loaded mechanism |
US6551302B1 (en) | 1997-09-24 | 2003-04-22 | Michael J. Rosinko | Steerable catheter with tip alignment and surface contact detector |
US6591129B1 (en) | 1996-02-15 | 2003-07-08 | Biosense, Inc. | Method for treating tissue through injection of a therapeutic agent |
US6676679B1 (en) | 1999-11-05 | 2004-01-13 | Boston Scientific Corporation | Method and apparatus for recurrent demand injury in stimulating angiogenesis |
US6695808B2 (en) | 2000-03-23 | 2004-02-24 | Scimed Life Systems, Inc. | Pressure sensor for therapeutic delivery device and method |
US6748258B1 (en) | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
US6746686B2 (en) | 2000-01-24 | 2004-06-08 | Biocompatibles Uk Limited | Coated implants |
US6855160B1 (en) | 1999-08-04 | 2005-02-15 | C. R. Bard, Inc. | Implant and agent delivery device |
US6949117B2 (en) | 1998-09-30 | 2005-09-27 | C. R. Bard, Inc. | Vascular inducing implants |
US6986784B1 (en) | 1999-05-14 | 2006-01-17 | C. R. Bard, Inc. | Implant anchor systems |
US7147633B2 (en) | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
US7214223B2 (en) | 2000-03-24 | 2007-05-08 | Boston Scientific Scimed, Inc. | Photoatherolytic catheter apparatus and method |
US7232421B1 (en) | 2000-05-12 | 2007-06-19 | C. R. Bard, Inc. | Agent delivery systems |
EP1753451A4 (fr) * | 2004-06-07 | 2008-11-12 | Conor Medsystems Inc | Apport local de facteurs de croissance pour la transplantation de cellules souches |
US7588554B2 (en) | 2000-06-26 | 2009-09-15 | Boston Scientific Scimed, Inc. | Method and apparatus for treating ischemic tissue |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5287861A (en) * | 1992-10-30 | 1994-02-22 | Wilk Peter J | Coronary artery by-pass method and associated catheter |
US5429144A (en) * | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5527337A (en) * | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
-
1997
- 1997-06-11 WO PCT/US1997/010024 patent/WO1997047253A1/fr active Application Filing
- 1997-06-11 AU AU33085/97A patent/AU3308597A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527337A (en) * | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
US5287861A (en) * | 1992-10-30 | 1994-02-22 | Wilk Peter J | Coronary artery by-pass method and associated catheter |
US5429144A (en) * | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
Non-Patent Citations (2)
Title |
---|
AMERICAN HEART JOURNAL, September 1983, Volume 106, Number 3, LEE et al., "Effects of Laser Irradiation Delivered by Flexible Fiberoptic System on the Left Ventricular Internal Myocardium", pages 587-590. * |
IEEE JOURNAL OF QUANTUM ELECTRONICS, December 1984, Vol. QE-20, No. 12, ISNER et al., "The Current Status of Lasers in Treatment of Cardiovascular Disease", pages 1406-1420. * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
US6591129B1 (en) | 1996-02-15 | 2003-07-08 | Biosense, Inc. | Method for treating tissue through injection of a therapeutic agent |
US6067988A (en) * | 1996-12-26 | 2000-05-30 | Eclipse Surgical Technologies, Inc. | Method for creation of drug delivery and/or stimulation pockets in myocardium |
US6482220B1 (en) | 1996-12-26 | 2002-11-19 | Eclipse Surgical Technologies Inc. | Method and apparatus for creation of drug delivery and/or stimulation pockets in myocardium |
US5999678A (en) * | 1996-12-27 | 1999-12-07 | Eclipse Surgical Technologies, Inc. | Laser delivery means adapted for drug delivery |
US5925012A (en) * | 1996-12-27 | 1999-07-20 | Eclipse Surgical Technologies, Inc. | Laser assisted drug delivery |
US6551302B1 (en) | 1997-09-24 | 2003-04-22 | Michael J. Rosinko | Steerable catheter with tip alignment and surface contact detector |
WO1999039624A1 (fr) * | 1998-02-05 | 1999-08-12 | Biosense Inc. | Administration de medicament intracardiaque |
US6254573B1 (en) | 1998-02-05 | 2001-07-03 | Biosense, Inc. | Intracardiac drug delivery device utilizing spring-loaded mechanism |
US6309370B1 (en) | 1998-02-05 | 2001-10-30 | Biosense, Inc. | Intracardiac drug delivery |
US6733488B2 (en) | 1998-09-30 | 2004-05-11 | C.R. Bard, Inc. | Transthoracic drug delivery device |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
US6517527B2 (en) | 1998-09-30 | 2003-02-11 | C. R. Bard, Inc. | Transthoracic drug delivery device |
US6949117B2 (en) | 1998-09-30 | 2005-09-27 | C. R. Bard, Inc. | Vascular inducing implants |
US6986784B1 (en) | 1999-05-14 | 2006-01-17 | C. R. Bard, Inc. | Implant anchor systems |
US7147633B2 (en) | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
US6855160B1 (en) | 1999-08-04 | 2005-02-15 | C. R. Bard, Inc. | Implant and agent delivery device |
US6748258B1 (en) | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
US6676679B1 (en) | 1999-11-05 | 2004-01-13 | Boston Scientific Corporation | Method and apparatus for recurrent demand injury in stimulating angiogenesis |
US7392077B2 (en) | 1999-11-05 | 2008-06-24 | Boston Scientific Scimed, Inc. | Method for treating a patient at risk of loss of cardiac function by cardiac ischemia |
US6746686B2 (en) | 2000-01-24 | 2004-06-08 | Biocompatibles Uk Limited | Coated implants |
US6695808B2 (en) | 2000-03-23 | 2004-02-24 | Scimed Life Systems, Inc. | Pressure sensor for therapeutic delivery device and method |
US7211063B2 (en) | 2000-03-23 | 2007-05-01 | Boston Scientific Scimed, Inc. | Pressure sensor for therapeutic delivery device and method |
US7214223B2 (en) | 2000-03-24 | 2007-05-08 | Boston Scientific Scimed, Inc. | Photoatherolytic catheter apparatus and method |
US7232421B1 (en) | 2000-05-12 | 2007-06-19 | C. R. Bard, Inc. | Agent delivery systems |
US7588554B2 (en) | 2000-06-26 | 2009-09-15 | Boston Scientific Scimed, Inc. | Method and apparatus for treating ischemic tissue |
US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
EP1753451A4 (fr) * | 2004-06-07 | 2008-11-12 | Conor Medsystems Inc | Apport local de facteurs de croissance pour la transplantation de cellules souches |
Also Published As
Publication number | Publication date |
---|---|
AU3308597A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997047253A1 (fr) | Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur | |
US6585716B2 (en) | Method of treating the heart | |
US5797870A (en) | Pericardial delivery of therapeutic and diagnostic agents | |
US6224584B1 (en) | Therapeutic and diagnostic agent delivery | |
US5840059A (en) | Therapeutic and diagnostic agent delivery | |
US7033372B1 (en) | Corkscrew reinforced left ventricle to coronary artery channel | |
US6224566B1 (en) | Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium | |
JP4224608B2 (ja) | 注入療法用装置 | |
US6508783B2 (en) | Ultrasound method for revascularization and drug delivery | |
US20030181843A1 (en) | Device and method providing arterial blood flow for perfusion of ischemic myocardium | |
US20100179643A1 (en) | Device and method for treating ischemic heart disease | |
WO1999029251A1 (fr) | Procede et appareil pour la liberation d'agents therapeutiques dans le coeur | |
US20020029037A1 (en) | Method and apparatus for percutaneous trans-endocardial reperfusion | |
US5873366A (en) | Method for transmyocardial revascularization | |
RU2026640C1 (ru) | Способ хирургического лечения ишемической болезни сердца | |
JPH1033550A (ja) | レーザ活用経心筋血管再生および他の用途のための深さ止め装置および方法 | |
WO1998057591A1 (fr) | Pontage cavite-artere percutane | |
Mack et al. | Minimally invasive thoracoscopically assisted coronary artery bypass surgery | |
WO2001010340A1 (fr) | Canal entre ventricule gauche et artere coronaire renforce par un serpentin | |
US6325813B1 (en) | Method and apparatus for stabilizing vascular wall | |
Shawl et al. | Procedural results and early clinical outcome of percutaneous transluminal myocardial revascularization | |
EP1188417A2 (fr) | Procédé et dispositif pour l'administration d'agents thérapeutiques dans le coeur | |
SU1754128A1 (ru) | Способ лечени ишемической болезни сердца | |
US20020121280A1 (en) | Method for myocardial revascularization | |
JP2002538930A (ja) | 心筋層横断の血管再構築のための加圧液体噴射の外科器具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98501769 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |